ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn’t hit its main goal.

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis drug and reported disappointing results from a late-stage study, sending ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Share on Pinterest Researchers say a molecule-based drug could prove to be a new treatment for multiple sclerosis. Bloomberg Creative/Getty Images Researchers are reporting they have looked at the ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in ...